Is NAGE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NAGE. It does not provide personalized investment advice.

NAGE (Niagen Bioscience, Inc. Common Stock) Stock Analysis - Financials

Niagen Bioscience, Inc. Common Stock (NAGE) is a publicly traded Healthcare sector company. As of August 24, 2026, NAGE trades at $3.21 with a market cap of $253.99M and a P/E ratio of 14.59. NAGE moved +1.90% today. Year to date, NAGE is -49.53%; over the trailing twelve months it is -67.14%. Its 52-week range spans $2.87 to $14.69. Analyst consensus is strong buy with an average price target of $10.20. Rallies surfaces NAGE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are NAGE's key financials?

NAGE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NAGE recently traded at $3.21. Market cap is $253.99M. P/E ratio is 14.59. Revenue is $129.42M.

NAGE Key Metrics

Key financial metrics for NAGE
Metric	Value
Price	$3.21
Market Cap	$253.99M
P/E Ratio	14.59
EPS	$0.22
Dividend Yield	0.00%
52-Week High	$14.69
52-Week Low	$2.87
Volume	310.80K
Avg Volume	0
Revenue (TTM)	$129.42M
Net Income	$17.38M
Gross Margin	64.28%

NAGE Analyst Consensus

5 analysts cover NAGE: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.20.

Common questions about NAGE

What are NAGE's key financials?: NAGE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NAGE recently traded at $3.21. Market cap is $253.99M. P/E ratio is 14.59. Revenue is $129.42M.
Is NAGE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NAGE. It does not provide personalized investment advice.